Cancer Diagnostics Market

Executive Summary

Cancer Diagnostics Market was valued at US $19.26 billion in 2021 and is projected to grow at 11.99% CAGR over the forecast period to reach US $37.99 billion by 2027. Cancer Diagnostics Market represented US $3.90 billion opportunity over 2019-2021 and estimated to create US $18.73 billion opportunity in 2027 over 2021.

Cancer Diagnostics from Consainsights analyses the Cancer Diagnostics Market in the Life Sciences industry over the forecast period to 2027.

Cancer Diagnostics research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Cancer Diagnostics segmentation includes Product, Technology, Application, End-user, Region and Geography.

Based on the Product, the Cancer Diagnostics analysis covers Consumables, Instruments.

In Product segment, Consumables segment has highest cagr growth of 10.59%.

Based on the Technology, the Cancer Diagnostics analysis covers IVD Testing, Imaging Technologies, Biopsies.

In Technology segment, IVD Testing segment has highest cagr growth of 10.59%.

Based on the Application, the Cancer Diagnostics analysis covers Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, Other Cancers.

In Application segment, Breast Cancer segment has highest cagr growth of 10.59%.

Based on the End-user, the Cancer Diagnostics analysis covers Hospitals, Diagnostic Laboratories.

In End-user segment, Hospitals segment has highest cagr growth of 10.59%.

Based on the Region, the Cancer Diagnostics analysis covers North America, Europe, Asia-Pacific, Rest of the World.

In Region segment, North America segment has highest cagr growth of 10.59%.

Based on the region, the Cancer Diagnostics analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Key Players, Start-Up/Sme Players and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Product

Introduction

In 2021, Consumables segment has the highest revenue of US $15.94 billion and is expected to grow at CAGR of 10.59% by 2027 Consumables segment has highest cagr growth of 10.59%.

Consumables

Consumables segment was valued at US $12.71 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $31.43 billion by 2027. Consumables segment represented US $3.23 billion opportunity over 2019-2021 and estimated to create US $15.50 billion opportunity in 2027 over 2021.

Instruments

Instruments segment was valued at US $2.65 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $6.56 billion by 2027. Instruments segment represented US $0.67 billion opportunity over 2019-2021 and estimated to create US $3.23 billion opportunity in 2027 over 2021.

Technology

Introduction

In 2021, IVD Testing segment has the highest revenue of US $13.37 billion and is expected to grow at CAGR of 10.59% by 2027 IVD Testing segment has highest cagr growth of 10.59%.

IVD Testing

IVD Testing segment was valued at US $10.66 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $26.37 billion by 2027. IVD Testing segment represented US $2.71 billion opportunity over 2019-2021 and estimated to create US $13.00 billion opportunity in 2027 over 2021.

Imaging Technologies

Imaging Technologies segment was valued at US $4.30 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $10.63 billion by 2027. Imaging Technologies segment represented US $1.09 billion opportunity over 2019-2021 and estimated to create US $5.24 billion opportunity in 2027 over 2021.

Biopsies

Biopsies segment was valued at US $0.40 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $0.99 billion by 2027. Biopsies segment represented US $0.10 billion opportunity over 2019-2021 and estimated to create US $0.49 billion opportunity in 2027 over 2021.

Application

Introduction

In 2021, Breast Cancer segment has the highest revenue of US $8.43 billion and is expected to grow at CAGR of 10.59% by 2027 Breast Cancer segment has highest cagr growth of 10.59%.

Breast Cancer

Breast Cancer segment was valued at US $6.72 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $16.62 billion by 2027. Breast Cancer segment represented US $1.71 billion opportunity over 2019-2021 and estimated to create US $8.20 billion opportunity in 2027 over 2021.

Lung Cancer

Lung Cancer segment was valued at US $4.72 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $11.68 billion by 2027. Lung Cancer segment represented US $1.20 billion opportunity over 2019-2021 and estimated to create US $5.76 billion opportunity in 2027 over 2021.

Colorectal Cancer

Colorectal Cancer segment was valued at US $2.28 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $5.64 billion by 2027. Colorectal Cancer segment represented US $0.58 billion opportunity over 2019-2021 and estimated to create US $2.78 billion opportunity in 2027 over 2021.

Melanoma

Melanoma segment was valued at US $0.91 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $2.25 billion by 2027. Melanoma segment represented US $0.23 billion opportunity over 2019-2021 and estimated to create US $1.11 billion opportunity in 2027 over 2021.

Other Cancers

Other Cancers segment was valued at US $0.72 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $1.79 billion by 2027. Other Cancers segment represented US $0.18 billion opportunity over 2019-2021 and estimated to create US $0.88 billion opportunity in 2027 over 2021.

End-user

Introduction

In 2021, Hospitals segment has the highest revenue of US $14.74 billion and is expected to grow at CAGR of 10.59% by 2027 Hospitals segment has highest cagr growth of 10.59%.

Hospitals

Hospitals segment was valued at US $11.76 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $29.08 billion by 2027. Hospitals segment represented US $2.99 billion opportunity over 2019-2021 and estimated to create US $14.34 billion opportunity in 2027 over 2021.

Diagnostic Laboratories

Diagnostic Laboratories segment was valued at US $3.60 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $8.91 billion by 2027. Diagnostic Laboratories segment represented US $0.92 billion opportunity over 2019-2021 and estimated to create US $4.39 billion opportunity in 2027 over 2021.

Region

Introduction

In 2021, North America segment has the highest revenue of US $7.91 billion and is expected to grow at CAGR of 10.59% by 2027 North America segment has highest cagr growth of 10.59%.

North America

North America segment was valued at US $6.31 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $15.60 billion by 2027. North America segment represented US $1.60 billion opportunity over 2019-2021 and estimated to create US $7.69 billion opportunity in 2027 over 2021.

Europe

Europe segment was valued at US $3.64 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $8.99 billion by 2027. Europe segment represented US $0.92 billion opportunity over 2019-2021 and estimated to create US $4.43 billion opportunity in 2027 over 2021.

Asia-Pacific

Asia-Pacific segment was valued at US $3.85 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $9.52 billion by 2027. Asia-Pacific segment represented US $0.98 billion opportunity over 2019-2021 and estimated to create US $4.70 billion opportunity in 2027 over 2021.

Rest of the World

Rest of the World segment was valued at US $1.57 billion in 2019 and is projected to grow at 10.59% CAGR over the forecast period to reach US $3.87 billion by 2027. Rest of the World segment represented US $0.40 billion opportunity over 2019-2021 and estimated to create US $1.91 billion opportunity in 2027 over 2021.